185 related articles for article (PubMed ID: 15539807)
21. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
22. Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults.
Hubina E; Mersebach H; Rasmussen AK; Juul A; Sneppen SB; Góth MI; Feldt-Rasmussen U
Horm Res; 2004; 61(5):211-7. PubMed ID: 14752209
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular disease and risk factors: the role of growth hormone.
Isgaard J
Horm Res; 2004; 62 Suppl 4():31-8. PubMed ID: 15591764
[TBL] [Abstract][Full Text] [Related]
24. Abuse of recombinant human growth hormone: studies in two different dog models.
Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
[TBL] [Abstract][Full Text] [Related]
25. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
26. Advances in growth hormone therapy: a new registry tool.
Pugeat M
Horm Res; 2004; 62 Suppl 4():2-7. PubMed ID: 15591760
[TBL] [Abstract][Full Text] [Related]
27. New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain.
Taghizadeh B; Jaafari MR; Zarghami N
Front Endocrinol (Lausanne); 2022; 13():963336. PubMed ID: 36263321
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of a preservative system in an oily preparation.
De Spiegeleer B; Wattyn E; Slegers G; Veys P; Derrieu G; Van Vooren L
Pharmazie; 2006 Jun; 61(6):545-51. PubMed ID: 16826975
[TBL] [Abstract][Full Text] [Related]
29. Status of long-acting-growth hormone preparations--2015.
Høybye C; Cohen P; Hoffman AR; Ross R; Biller BM; Christiansen JS;
Growth Horm IGF Res; 2015 Oct; 25(5):201-6. PubMed ID: 26187188
[TBL] [Abstract][Full Text] [Related]
30. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
Cutfield WS; Lundgren F
Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
[TBL] [Abstract][Full Text] [Related]
32. Myalgia and elevated creatine kinase activity associated with subcutaneous injections of diluent.
Bach MA; Blum DM; Rose SR; Charnas LR
J Pediatr; 1992 Oct; 121(4):650-1. PubMed ID: 1403405
[TBL] [Abstract][Full Text] [Related]
33. The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age.
Kappelgaard AM; Laursen T
Growth Horm IGF Res; 2011 Dec; 21(6):305-13. PubMed ID: 22019012
[TBL] [Abstract][Full Text] [Related]
34. Comparison of injection dose force, accuracy and precision among three growth hormone injection devices.
Kappelgaard AM; Hansen NÅ
Expert Rev Med Devices; 2013 May; 10(3):321-7. PubMed ID: 23560872
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial preservative use in parenteral products: past and present.
Meyer BK; Ni A; Hu B; Shi L
J Pharm Sci; 2007 Dec; 96(12):3155-67. PubMed ID: 17722087
[TBL] [Abstract][Full Text] [Related]
36. Automatic needle insertion diminishes pain during growth hormone injection.
Main KM; Jørgensen JT; Hertel NT; Jensen S; Jakobsen L
Acta Paediatr; 1995 Mar; 84(3):331-4. PubMed ID: 7780258
[TBL] [Abstract][Full Text] [Related]
37. Improvement of patient convenience in treatment with growth hormone.
Jørgensen JT
J Pediatr Endocrinol; 1994; 7(2):175-80. PubMed ID: 8061763
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous Injection Site Pain of Formulation Matrices.
Shi GH; Pisupati K; Parker JG; Corvari VJ; Payne CD; Xu W; Collins DS; De Felippis MR
Pharm Res; 2021 May; 38(5):779-793. PubMed ID: 33942212
[TBL] [Abstract][Full Text] [Related]
39. Local tolerance of subcutaneous injections.
Fransson J; Espander-Jansson A
J Pharm Pharmacol; 1996 Oct; 48(10):1012-5. PubMed ID: 8953501
[TBL] [Abstract][Full Text] [Related]
40. Developing long-acting growth hormone formulations.
Cawley P; Wilkinson I; Ross RJ
Clin Endocrinol (Oxf); 2013 Sep; 79(3):305-9. PubMed ID: 23662913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
